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a  b  s  t  r  a  c  t
Eicosanoids  are  potent  lipid mediators  of  inﬂammation  and  are  known  to  play  an  important  role  in
numerous  pathophysiological  processes.  Furthermore,  inﬂammation  has been  proven  to  be a  mediator
of  diseases  such  as hypertension,  atherosclerosis,  Alzheimer’s  disease,  cancer  and  rheumatoid  arthritis.
Hence,  these  lipid  mediators  have  gained  signiﬁcant  attention  in  recent  years.  This  review focuses  on
chromatographic  and  mass  spectrometric  methods  that have  been  used  to  analyze  arachidonic  acid  and its
metabolites  in  brain  tissue.  Recently  published  analytical  methods  such  as LC–MS/MS  and  GC–MS/MS  are
discussed  and  compared  in  terms  of  limit  of quantitation  and  sample  preparation  procedures,  includingrain tissue
ltra high pressure liquid
hromatography–mass spectrometry
igh pressure liquid
hromatography–mass spectrometry
as chromatography–mass spectrometry
solid  phase  extraction  and  derivatization.  Analytical  challenges  are  also  highlighted.
©  2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).andem mass spectrometry
. Introduction
Eicosanoids are speciﬁc biomarkers of inﬂammation. Their
iosynthesis from polyunsaturated fatty acids can be catalyzed
y cyclooxygenase (COX-2), lipoxygenases (LOX), and cytochrome
450 enzymes. Depending on the mechanism/pathway of biosyn-
hesis and parent molecule, different classes of eicosanoids are
eﬁned. Brain lipids such as neuroprostanes are produced by per-
xidation of docosahexaenoic acid. These lipids are different from
icosanoids and will not be the subject of this review. This article
ocuses on eicosanoids from Arachidonic Acid (AA).
Arachidonic acid (-6 polyunsaturated fatty acid) can be
etabolized to hydroxyeicosatetraenoic acids (HETEs), dihy-
roxyeicosatetraenoic acids (DiHETEs), epoxyeicosatreinoic acids
EETs), prostaglandins (PGs) and thromboxane (TX) (Fig. 1). These
ndogenous eicosanoids are present in small levels in biological
uids and tissues including the brain. In the brain, these markers
re important to maintain homeostasis and normal functions such
s synaptic plasticity related to long-term depression [1] and pro-
ecting cortical neurons against glutamate toxicity [2]. On the other
 This paper is part of the special issues ACIDS edited by Alexander A. ZOERNER
nd Dimitrios TSIKAS IG002157 Special Issue: Analysis of Acids/ZOERNER.
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ttp://dx.doi.org/10.1016/j.jchromb.2014.03.007
570-0232/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unhand, alterations in the levels of these lipids in the brain have been
associated with numerous diseases such as Alzheimer’s, Parkin-
son’s, Multiple sclerosis, schizophrenia, and epilepsy [3]. The past
decade has produced numerous excellent reviews describing the
metabolism of these lipid molecules and their role in diseases [4–7].
1.1. Cycloxygenase enzymes, prostaglandins and brain
Cyclooxygenase enzyme is present in the human body in the
form of three isozymes: COX-1, COX-2 and COX-3. COX-1 is thought
to be only responsible for maintaining homeostasis in numerous
physiological functions in the body [8]. COX-3, which was  dis-
covered only in 2003, is considered to be an intron-splice variant
of COX-1 [9]. On the other hand, COX-2 is involved in numerous
inﬂammatory processes [9]. Both COX-1 and COX-2 are expressed
in brain tissue [10]. Additionally COX-1 and COX-2 enzymes can
catalyze the reaction that converts arachidonic acid to a stable
hydroxyendoperoxide (PGH2) [11,12]. PGH2 is then converted into
primary prostanoids by various enzymes [11,12]. Prostanoids can
be classiﬁed into prostaglandins (PGE2, PGF2 and PGD2), prostacy-
clins (PGI2) and thromboxanes (TXA2). PGD2 is the most abundant
prostaglandin synthesized in the central nervous system. It not only
regulates functions like temperature and sleep [13] but it also pro-
tects the brain from excitotoxic injury [14]. PGE2 is involved in brain
maturation and in regulation of synaptic activity and plasticity [15].
Furthermore being one of the most abundant prostaglandins, PGE2
is involved in processes leading to classic signs of inﬂammation
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Nomenclature
AA Arachidonic acid
BHT Butylated hydroxyl toluene
CID Collision-induced dissociation
CLASS Comprehensive lipidomic analysis by separation
simpliﬁcation
COX Cyclooxygenase
CSF Cerebral spinal ﬂuid
CV Coefﬁcient of variance
CYP-450 Cytochrome P450
CyPGs Cyclopentenone prostaglandins
DiHETEs Dihydroxyeicosatetraenoic acids
DiHETrEs Dihydroxyeicosatreinoic acids
DTPA Diethylenetriaminepenta-acetic acid
ECNCI Electron capture negative chemical ionization
EDTA Ethylenediaminetetra-acetic acid
EETs Epoxyeicosatrienoic acids
ESI Electrospray ionization
ESI-LC-MS/MS Electrospray ionization coupled to high pres-
sure liquid chromatography with tandem mass
spectrometry
fmol Femtomol
GC Gas chromatography
GC-FID Gas chromatography-ﬂame ionization detection
GC–MS Gas chromatography–mass spectrometry
GC–MS/MS Gas chromatography–tandem mass spectrome-
try
GC–MS/NICI Negative ion chemical ionization coupled to gas
chromatography–mass spectrometry
HESI Heated electrospray ionization
HETEs Hydroxyeicosatetraenoic acids
HETP Height equivalent theoretical plates
HILIC Hydrophilic interaction chromatography
HPETEs Hydroxyperoxyeicosatetraenoic acid
HPLC High pressure liquid chromatography
HPLC-UV High pressure liquid chromatography-ultraviolet
detector
LC Liquid chromatography
LC–MS Liquid chromatography–mass spectrometry
LC–MS/MS Liquid chromatography–tandem mass spec-
trometry
LOD Limit of detection
LOQ Limit of quantitation
LOX Lipoxygenases
LTs Leukotrienes
MRM  Multiple reaction monitoring
MS  Mass spectrometry
MS/MS  Tandem mass spectrometry
NE-OTf 2-(2,3-naphthalimino)ethyl-
triﬂuoromethanesulphonate
NICI Negative ion chemical ionization
NP-HPLC Normal-phase high pressure liquid chromatogra-
phy
ODS-silica Octadecylsilyl-silica
PCA Principle component analysis
PFB Pentaﬂuorobenzyl
pg Picogram
PGH2 Hydroxyendoperoxide
PGs Prostaglandins
Q1 Quadrupole 1
RP-HPLC Reverse-phase high pressure liquid chromatogra-
phy
SAH Subarachnoid hemorrhage
sEH Soluble epoxide hydrolase
SIM Selective ion monitoring
sMRM Scheduled multiple reaction monitoring
SPE Solid phase extraction
SRM Selected reaction monitoring
SV Symptomatic cerebral vasospasm
TBI Traumatic brain injury
TLC Thin layer chromatography
TOF Time-of-ﬂight
TX Thromboxane
UPLC Ultra high pressure liquid chromatography
UPLC–MS/MS Ultra high pressure liquid chromatography–Q3 Quadrupole 3
Q-TOF Quadrupole time-of-tlight mass spectrometer
QTRAP Quadrupole-linear ion traptandem mass spectrometry
UV Ultraviolet
and pain [16]. PGF2 plays an important role in brain injury and pain
[16]. PGI2 and TXA2 are potent vasodilators and vasoconstrictors
respectively.
1.2. Lipoxygenase enzymes, leukotrienes and the brain
Lipoxygenease are a group of enzymes that catalyzes the reac-
tion, which involves the addition of oxygen to AA producing
hydroxyperoxyeicosatetraenoic acid (HPETEs) [17,18]. HPETE then
reduces to give leukotrienes (LTs) and hydroxyeicosatetraenoic
acid (HETEs) [19]. Cysteinyl leukotrienes, which include LTC4, LTD4
and LTE4, are found to alter cerebral vessel functions [20] and dis-
rupt the blood brain barrier [20]. Moreover, they have been related
to brain edema formation [20]. They are also produced in response
to numerous acute brain injuries [21]. LTB4 may also be involved in
the pathogenesis of ischemic brain edema [22]. Another role LTB4
plays in inﬂammation is attracting leukocytes [97]. Inﬂammation
as a result of alterations in blood ﬂow and vascular permeability
can be described by the actions of LTC4 and LTD4 [97]. Leukotrienes
can be involved in inﬂammatory diseases such as asthma. HETEs
are potent vasoactive agents and are altered in cerebrovascular
pathologies [22].
1.3. Cytochrome P450 enzymes (CYP-450), DiHETEs, HETEs and
the brain
AA undergoes metabolism by CYP-450 to give epoxye-
icosatrienoic acid (EETs). CYP enzyme produces four regioisomers
of EET from AA: 5,6-, 8,9-, 11,12-, and 14,15-EET [23]. EETs are
quickly metabolized in the presence of soluble epoxide hydrolase
(sEH) to the corresponding inactive diols, the DiHETEs [24,25]. In
the brain, EETs are involved in controlling the cerebral blood ﬂow
(CBF) [26]. They are neuroprotective agents because of their anti-
inﬂammatory and anti-thrombotic effects [26]. Zhang et al. found
that deletion of sEH, the enzyme that metabolizes EETs to DiHETEs,
is protective against ischemic brain injury [27].
2. Quantiﬁcation of eicosanoids
Currently, immunoassays [28], GC–MS [29], LC–MS [30] and
LC–MS/MS [31,32] have been used to analyze eicosanoids. For
a long time, immunoassays, (enzyme-linked immunoassays and
radio-labeled immunoassays) were considered to be the standard
method for lipid analysis. Though these assays were sensitive, they
suffered from reproducibility and reduced speciﬁcity. A regular
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cFig. 1. Oxidative pathway of arachido
nalysis using HPLC with UV detection is difﬁcult, as most of these
ipid molecules do not have good chromophores. GC–MS and
C–MS/MS in negative ion chemical ionization mode have been
uccessfully used to analyze some of these markers. The disadvan-
age is that, to make it suitable for labile compounds like the EETs,
he analyte needs to undergo puriﬁcation followed by derivatiza-
ion. Similarly HPLC coupled to ﬂuorescent detectors require these
ompounds to be derivatized to a complex that ﬂuoresces, as these
ompounds contain no aromatic or naturally ﬂuorescing systems
33]. Derivatization makes the analysis laborious, expensive and
ime consuming. The more popular choice when it comes to detec-
ion of these biomarkers is LC–MS. One of the reasons is that mass
pectrometry (MS) allows quantiﬁcation at very low levels in com-
lex matrices. Moreover, mass spectrometry gives better isomer
eparation when compared to HPLC-UV and immunoassays.
In regards to analysis of the brain tissue, the two most important
teps are extraction and sample preparation. These are important,
s the complex brain matrix produces high chemical background
oise, thus reducing selectivity and sensitivity. This review focuses
n the various strategies that have been used to analyze eicosanoids
n brain in recent years.
.1. Sample preparation and extraction procedures
Analyzing eicosanoids from biological samples requires extrac-
ion and puriﬁcation of the analyte in order to ensure the analyte
s present and free of any interfering impurities. The amount
f analyte present depends upon the sample matrix. In various
atrices such as the brain, arachidonic acid metabolites exist in
xtremely low concentrations and extraction is required to increase
peciﬁcity and sensitivity [34]. Eicosanoids can be extracted using
rganic solvent (liquid/liquid) or solid phase extraction (SPE).
n choosing an extraction method it is important to consider
hat the method is fast, reproducible and cost effective. The
icosanoids must not be altered by the extraction procedure; there-
ore, extremes of pH must be avoided [41]. Nevertheless, adjusting
he pH can increase efﬁciency. Signal suppression is a signiﬁ-
ant problem in analysis of biological samples. Common tissue
xtraction procedures are complicated by the control of matrix
ffects and differences in physiochemical properties of analytes
56]. Since eicosanoids precursors are unstable in the matrix, new
icosanoids may  be generated during the extraction process. Cru-
ial functions to the extraction process such as homogenizationd by COX, LOX and CYP 450 enzymes.
can activate eicosanoid synthesis; therefore, inhibitors and other
drugs such as indomethacin, ethylenediaminetetra-acetic acid
(EDTA), diethylenetriaminepenta-acetic acid (DTPA), and butylated
hydroxyl toluene (BHT) are incorporated into the extraction pro-
cess to limit eicosanoid formation from the extraction [61].
Many methods are reported in the literature for the extraction of
eicosanoids from tissues, most employ the Folch or Bligh and Dyer
extraction protocols with modiﬁcations [35,36]. The Folch proce-
dure uses chloroform/methanol in a 2:1 volume ratio at 20 times
the amount of sample [35]. Partitioning of the two  layers can be
achieved using a saline solution of ¼ the total volume added. This
will also attain a lower layer consisting of all lipids and an upper
layer consisting of contaminants. In the end a solution composed
of the ratio 8:4:3 chloroform/methanol/water should be utilized
to afﬁrm lipid separation into the chloroform layer. Bligh and Dyer
adapted the procedure set forth by Folch and improved the amount
of solvent used as well as decreased the time of extraction and anal-
ysis. In the adapted method 3 mL  of 2:1 methanol/chloroform was
used per gram or mL  of sample. Following mixing, 1 mL  chloro-
form and 1.8 mL  water were added to partition the solution into
two phases. Using chloroform to re-extract the tissue improves
the yield of the lipids. Depending on the desired form of anal-
ysis, methods may  employ the Folch [63–65] or Bligh and Dyer
procedures for extraction of eicosanoids; however, if high sensi-
tivity is required as in mass spectrometry, further puriﬁcation may
be necessary. Some liquid/liquid extractions that are more speciﬁc
for brain eicosanoids include hexane/2-propanol [37,59,60], ether
[38], acetone/chloroform [39,40]. Saunders and Horrocks exhib-
ited a 12–37% increase in recovery of prostaglandins from bovine
brain using hexane/isopropanol as compared to the Folch proce-
dure [37]. Acidiﬁcation of the lower layer allows the eicosanoids to
be in a non-ionized form and can be extracted into organic solvents.
Caution must be taken during this step as excess acidiﬁcation can
lead to eicosanoid alterations [40]. Tajima et al. modiﬁed the Bligh
and Dyer procedure for analysis of brain tissue for Alzheimer’s dis-
ease, in which the liquid/liquid extraction is further puriﬁed via
SPE [50]. Similarly, Axelsen and Murphy execute a modiﬁed proce-
dure of Bligh and dyer for extraction of arachidonic acid in mouse
brains to study neurogenerative disorders [51]. In a recent study,
extractions of prostaglandins from brain samples were assessed
and compared to achieve the best recoveries and lowest detec-
tion limits [39]. Golovko et al. explored brain extraction of PGE2,
PGD2, TXB2, PGF2 and 6-oxo-PGF1 with methanol followed by
omato
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PE, diethyl ether, hexane/2-propanol and with acetone. Acetone
xtraction followed by liquid/liquid extraction presented the low-
st background noise thus increasing the sensitivity the LC–MS/MS
nalysis [39,49]. An increase in sensitivity is attributed to the puriﬁ-
ation of the prostaglandins by acetone. Liquid/liquid extractions
equire a large amount of solvent, which increases cost of analysis
s well as decreases the extraction efﬁciency and mass spectrom-
try sensitivity [38]. Brose et al. challenged these issues using a
ne step methanol extraction, consequently increasing efﬁciency
nd sensitivity and decreasing analysis time [42]. Substitution of
ethanol for acetone/chloroform exhibited superior performance
ver other liquid/liquid extractions and SPE’s. The use of methanol
ather than acetone/chloroform improved the recovery of internal
tandards to (96.7 ± 9.9%), which is a 20% increase over previously
eported multiple step liquid/liquid extractions [42]. A concern
n using the methanol procedure to extract prostaglandins and
soprostanes from brain tissue is that the methanol extracts will
ontain hydrophobic lipids that are not eluted from the column
uring analysis and could therefore overtime shift the retention
ime of other components by binding to the column [42]. Likewise,
asaka et al. used methanol to extract arachidonic acid from mouse
erebrum. The tissue was homogenized and centrifuged three times
n methanol to increase the extraction efﬁciency and extrude as
any contaminants as possible [44]. A 95% recovery was consis-
ently reported for the extraction of arachidonic acid by Yasaka
t al. Urban et al. evaluated the advantages and shortcomings
f four extraction solvents for extraction of prostaglandins from
rain tissue; ethanol/dichloromethane (1:1), ethanol/10 mM phos-
hate buffer (85:15), methanol/10 mM phosphate buffer (85:15)
nd 10 mM phosphate buffer [56]. Using ethanol/10 mM phosphate
uffer as the extraction solvent, the prostaglandins demonstrated
he most reproducible results, with a coefﬁcient of variance <15% in
omparison to ethanol/dichloromethane (<20%), methanol/10 mM
hosphate buffer (<25%) and 10 mM phosphate buffer (<30%).
In addition to the large solvent volumes required, other dis-
dvantages of liquid/liquid extractions are that they are time
onsuming and potential error is introduced with each addition
f solvent. To lower the amount of solvent consumption, decrease
ample analysis time, lower the cost per sample and increase con-
istency, SPE’s have increased in popularity. SPE concentrates the
nalyte, thus increasing the sensitivity as well as improving detec-
ion limits. Additionally, it removes interfering compounds and
mpurities, thus protecting analytical systems and increasing efﬁ-
iency. Higher and more reproducible recoveries are experienced
s a result of cleaner extracts as well as tunable selectivity, i.e.
Fig. 2. Yue et al. extraction of eicosangr. B 964 (2014) 50–64 53
choice of solvents for elution. SPE cartridges come in reverse phase
(C18), normal phase (silica) and ion exchange (anion or cation).
The basic principle behind reverse-phase SPE is that the aliphatic
moieties in the lipids can interact with the non-polar stationary
phases; consequently, allowing them to be retained and separated
from impurities. Various solvents can be used to concentrate the
analyte by releasing non-lipid contaminants. Finally the sample
can be released by washing the column with a non-polar solvent.
SPE is similar to HPLC and differs mainly in the packing of the
columns; SPE columns use large silica particles in comparison to
micron particle sized HPLC columns. An added advantage of SPE is
that it can be combined directly with LC, thus eliminating sample
loss and also offering the potential for a fully automated system.
A simple procedure to extract eicosanoids from biological tissues
is demonstrated by Powell [34]. Eicosanoids are extracted on a
hydrophilic stationary phase containing octadecylsilyl-silica (ODS-
silica). Samples are loaded onto the column with a 15% methanol
solution and washed with 15% methanol, water, petroleum ether
and ﬁnally methyl formate to elute the eicosanoids [34]. For the
extraction of prostaglandins the percent of methanol solution
should be lowered to <10% to yield the highest recoveries. In con-
trast, Powell demonstrated that the extraction of unmetabolized
arachidonic acid requires a methanol solution of 30% to accom-
plish recoveries >80%. In our group, Yue et al. extracted endogenous
eicosanoid metabolites in rat brain using an Oasis® HLB SPE car-
tridge (Fig. 2) eluting analytes with acetonitrile and ethyl acetate
and evaporated the remaining solvent under argon [33,43]. The
extraction efﬁciency and the %RSD for PG’s, DiHETrE’s, HETE’s,
EET’s and AA was 72.13–99.56% and 1.93–14.73% respectively,
indicating a reproducible extraction and a reliable bioanalytical
method [43]. This extraction procedure reported interference of
the components of the SPE with PGF2 and 15-HETE. Similarly,
Masoodi and Nicolaou performed an extraction of 27 prostanoids
including prostaglandins, prostacyclines, thrombroxanes, dihy-
droprostaglandins and isoprostanes from brain samples on C-18
Phenomenex SPE cartridge, eluting analytes with methyl formate
and achieved percent recoveries of 84–110% [31].
Brain tissue has high moisture and fat content [33]. Therefore,
since eicosanoids are lipophilic and will bind to fats, choice of
solvent during an extraction is vital. For SPE of eicosanoids from
brain tissue, solvents must be chosen that dissolve eicosanoids,
permeate through brain tissue matrix, break down the tissues and
release the eicosanoids and ﬁnally induce protein precipitation
[33]. Acidic conditions can be used to reduce protein binding as
well as warrant the free carboxylic acid form of eicosanoids. In
oid metabolites from rat brain.
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ur group, Yue et al. established that methanol and formic acid
hould be used for SPE, as they are easily evaporated and com-
atible with the system. Additionally, the choice of SPE cartridge
as evaluated and Oasis® HLB cartridges were chosen as they
ielded reproducible results in wet and dry conditions. Many other
icosanoid extraction procedures that also make use of SPE have
een reported [30,45–48,52–54,57,58,62,66]. Miller et al. extracted
0-HETE, 15-HETE, 12-HETE, 14,15-EET, 11,12-EET, 8,9-EET, 14,15-
iHETrE, 11,12-DiHETrE, 8,9-DiHETrE and 5,6-DiHETrE metabolites
f arachidonic acid in rat brain cortical tissue samples and achieved
ecoveries ranging from 73% to 94% as well as a %RSD of less than
6.75% [52]. A few disadvantages of SPE are that it can be time con-
uming depending upon the procedure utilized, SPE cartridges are
xpensive and for unstable eicosanoids a lengthy extraction process
ould be detrimental to further precise analysis of the metabolites.
In addition to the extraction procedure, care must be taken when
ampling the brain to ensure there is no post-mortem PG syn-
hesis. Brain PG mass is reported 10–40-fold lower using focused
icrowave irradiation as compared to decapitation [39,95,96]. In
ddition, PG’s can be synthesized during the extraction, which can
ontribute to higher and greater variability of PG mass found in
amples [39]. Golovko and Murphy established microwave irradia-
ion at 70–80 ◦C as an effective technique to heat-denature enzymes
n order to prevent post-mortem PG synthesis [39]. A concern with
icrowave irradiation is related to PG heat-destruction or trapping
enatured proteins. Golovko and Murphy illustrate that PG levels
etween microwaved and non-microwaved brains (at maximal PG
ormation) indicating PG’s aren’t trapped during the microwave
rocess and therefore recovery is not affected [39]. Microwave
rradiation prevents dramatic post-mortem induction in brain
icosanoids and allows for measurement of true eicosanoid levels.
Automated methods have been developed that exemplify
omparable precision and accuracy to manual operations, while
ncreasing the throughput of sample analysis [55]. A problem in
ample preparation often occurs in transfer of materials from the
xtraction to method of analysis (i.e. GC, LC). Eliminating human
ransfer of these materials will increase efﬁciency and decrease
ample loss. Advances in technology will allow for more of these
ypes of methods.
.2. Separation and detection
.2.1. Gas chromatography–mass spectrometry
Gas chromatography–mass spectrometry (GC–MS) was  for a
ong time a routine analytical technique for quantitation and struc-
ure interpretation of eicosanoids; however, because of the cost
f equipment and difﬁculty in sample preparation, fewer labora-
ories utilize GC–MS. For GC analysis, a molecule must be volatile
nd thermally stable, which are not properties that all eicosanoids
xpress. As a result, for analysis of eicosanoids derivatization of
arboxyl and hydroxyl groups is required to increase their volatility
41]. Following a derivatization step, many analytes can be detected
imultaneously. Some examples of derivatization methods are N-
cylation, methoximine formation, esteriﬁcation and trimethylsilyl
ther formation [41]. GC-Flame Ionization Detection (FID) is not fre-
uently used for quantitative analysis of eicosanoids; nevertheless,
osenberger et al. quantiﬁed prostaglandin methyl esters using a
C (Trace 2000, ThermoFinnigan, Houston, TX, USA) equipped with
 capillary column (SP 2330; 30 m × 0.32 mm i.d., Supelco, Belle-
onte, PA, USA) and a FID to determine that rat brain arachidonic
cid metabolism increases by infusion of bacterial lipopolysaccha-
ide [84]. The limit of quantitation (LOQ) was not reported but
ontrol samples of PGF1, PGF2, TXB2, PGD2 and PGE2 demon-
trated linearity to approximately 20 pmol/g of brain sample. FID
oes not demonstrate information concerning the mass of metabo-
ites, making structure elucidation unreasonable.gr. B 964 (2014) 50–64
Precise quantitation using GC-FID is contingent upon reso-
lution of chromatographic peaks, which is not always possible.
Instead, GC–MS is more frequently used as it allows detection of
eicosanoids down to picogram (pg) levels in biological samples.
GC–MS requires puriﬁcation steps following derivatization to void
any impurities formed during the derivatization process. Com-
mon  sample matrices analyzed by GC–MS are urine and plasma.
Still, methods have been reported for analysis of brain samples by
GC–MS. Ogorochi et al. determined the in situ contents of PGD2,
PGE2, PGF2 and 6-keto-PGF1 in regions of post-mortem human
brain [58]. This method challenges the notion that the concentra-
tion of PGF2 is the most abundant prostaglandin in post-mortem
brain samples, signifying its potential use as a biological indica-
tor in neural and glial cells as reported by Abdel-Halim et al. [89].
Ogorochi et al. establish that the concentrations of PGD2, PGE2 and
PGF2 are similar in post-mortem human brain samples and that
Abdel-Halim et al. reported values consistent with in vitro artiﬁcial
production of prostaglandins [58]. Distribution of the metabolites
in post-mortem human brain samples can be seen in [58] with
concentrations ranging from 0.06 to 41.3 ng/g wet weight. In a
slightly different scope metabolites of arachidonic acid in mice
brain samples were separated by normal-phase high pressure liq-
uid chromatography (NP-HPLC) and the structures of the identiﬁed
metabolites were conﬁrmed by GC–MS by Amruthesh et al. [75].
Methyl ether methoxylaminetrimethysilyl ether derivatives of 5-
HETE, 12-HETE and 15-HETE were assessed using electron impact
ionization MS  and pentaﬂuorobenzyl (PFB) ester derivatives of 5,6-
EET and 14,15-EET were analyzed using negative ion chemical
ionization MS.  GC–MS is frequently used as an analytical support
technique for conﬁrmation of structures separated by other chro-
matographic techniques. Yang et al. demonstrated a signiﬁcant
increase in arachidonic acid in the brain 24 h after a traumatic brain
injury (TBI) using GC–MS and principle component analysis (PCA)
to compare serum samples of TBI and normal rats [77].
Speciﬁc ionization techniques such as electron capture negative
chemical ionization (ECNCI) are commonly used for the detection
of eicosanoids following separation by GC. In negative ion chemi-
cal ionization (NICI) a carboxylate anion is observed in eicosanoid
analysis. A general method for analysis of arachidonic acid in var-
ious sections of mouse brain tissue using NICI coupled to GC–MS
is demonstrated in [51]. Levels of arachidonic acid in various lipid
species were reported from 78 to 492 nmol/g tissue. Wiswedel et al.
quantitated monohydroxyeicosatetraenoic acids (HETEs) and F2-
isoprostanes by GC–MS/NICI to study lipid peroxidation in rat brain
mitochondria [79]. After hydrogenation and SPE, PFB ester and
trimethylsilyl ether derivatives were formed for analysis of HETEs
and F2-isoprostanes by GC–MS/NICI. Quantitative analysis obtained
in selective ion monitoring (SIM) mode, monitoring the carboxylate
anion [M−181]− at m/z 399 for the HETEs reported the sum of the
HETEs (5-HETE, 8-HETE, 12-HETE and 15-HETE) content in the rat
brain mitochondria as 220 ± 40 pmol/mg protein [79]. Additionally,
monitoring the carboxylate anion [M−181]− at m/z 569, the content
of F2-isoprostanes (8-iso-PGF2, 9,11-PGF2 and 9,11-PGF2)
was 0.21–5.4 pmol/mg protein [79]. SIM requires careful extrac-
tion and puriﬁcation to ensure no interference from impurities
developed throughout the process. Although not brain analysis,
Nithipatikom et al. used GC–MS/NICI to analyze the release of
epoxyeicosatrienoic acids (EETs) (5,6-EET, 8,9-EET, 11,12-EET and
14,15-EETs), consequent dihydroxyeicosatrienoic acids (DiHETrEs)
and hydroxyeicosatetraenoic acids (HETEs) (19-HETE and 20-HETE)
into the coronary venous plasma during coronary artery occlu-
sion and reperfusion in anesthetized dogs [80]. After extraction,
pentaﬂuorobenzyl ester and pentaﬂuorobenzyl ester/trimethylsilyl
ether derivatives of EETs, DiHETrEs and 20-HETE respectively were
formed and detected by SIM at the appropriate m/z. The EETs
coeluted and therefore the limit of detection (LOD) is a sum of
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he total EETs. The limit of detection was 5, 40 and 15 pg for
he EETs, DiHETrEs and 20-HETE respectively [80]. Kadiiska et al.
escribe that the measurement of isoprostanes, speciﬁcally 8-iso-
GF2 by GC–MS/NICI is the most accurate approach for analysis
f oxidative stress [90]. In conjunction with that discovery, Mila-
ovic and Aschner demonstrated a procedure using GC–MS/NICI for
he measurement of F2-isoprostanes as markers of oxidative stress
n neuronal tissue, reporting the lower limit of detection for F2-
soprostanes to be in the low picogram range [81]. Tandem mass
pectrometry (MS/MS) instruments have gained interest recently in
oupling with various chromatography techniques. There are two
odes of operation a MS/MS  instrument can use, scanning mode
nd selected reaction monitoring (SRM) or multiple reaction moni-
oring (MRM)  mode. Scanning mode can be performed in the ﬁrst or
econd analyzer, in which a speciﬁed range of masses are studied.
n MRM  mode the collision-induced dissociation (CID) of precur-
or ions produces product ions, which increases the speciﬁcity of
icosanoid analysis [78]. Tandem MS  instruments increase sensitiv-
ty by monitoring the selected reaction rather than the selected ion.
n excellent review is written by Tsikas, thoroughly discussing the
se of GC–MS and GC–MS/MS for the analysis of the metabolites of
rachidonic acid for most biological samples, except the brain [76].
.2.2. Liquid chromatography
A survey evaluating liquid chromatography (LC) trends from the
revious decade indicates that reverse-phase high pressure liquid
hromatography (RP-HPLC) is the dominant LC analysis technique
71]. Previously thin layer chromatography (TLC) was  employed to
eparate eicosanoids; however, this technique required standards
o be available, which may  not exist for endogenous eicosanoids.
s compared to TLC, HPLC allows for better separation as a result
f a larger number of theoretical plates. Separation efﬁciency is
etermined by the particle size, pore size, surface area, stationary
hase and the chemistry of the substrate surface [82]. Addition-
lly because HPLC is a nondestructive technique, it can be used for
uriﬁcation purposes [72].
As a consequence of the isomeric and isobaric (ions with the
ame mass) nature of some of the metabolites of arachidonic
cid, chromatography is an essential step in quantiﬁcation. Vari-
us modes can be used to separate the metabolites of arachidonic
cid, RP-HPLC, NP-HPLC, chiral HPLC and hydrophilic interac-
ion chromatography (HILIC). Separation in RP-HPLC relies on the
ydrophobic properties of the analytes and therefore remains
he workhorse for separation of these metabolites. Studying the
etabolism of arachidonic acid in mouse brain microsomes, Qu
t al. were unable to separate 19-HETE and 20-HETE with RP-
PLC and employed NP-HPLC to determine the percentage of each,
9% and 45% respectively in the sample [73]. NP-HPLC is useful in
eparating various classes of metabolites. NP-HPLC is often used
ith chiral columns, improving the separation of enantiomers and
egioisomers [74]. Determining the ratio of PGE2/entPGE2 had not
een achieved with HPLC without the use of a derivatization step
ntil Brose et al. used chiral HPLC to prove they are present in equal
uantities in brain samples [49]. Because LC–MS emphasizes the
eed for volatile components, NP-HPLC is an often a good option.
P-HPLC can use solvents that cause concern for ﬂammability as a
esult of heating elements; however, electrospray ionization (ESI)
oes not require heating thus eliminating this concern. HILIC sepa-
ations can use a reverse-phase solvent system and achieve similar
eparation of eicosanoids performed by NP-HPLC. HILIC separations
an have increased MS  sensitivity because the effect of ion suppres-
ion is decreased. Ion-pairing reagents typically used in RP-HPLC
olvent may  not be required for HILIC separations of polar com-
ounds. Although methods are reported for HILIC separation of
icosanoids [91,93] it is to our knowledge that none thus far have
een speciﬁc for brain samples.gr. B 964 (2014) 50–64 55
While improved LC techniques achieve separation of the
metabolites of arachidonic acid, detection requires high sensitiv-
ity and speciﬁcity for a complex matrix such as the brain. An
HPLC equipped with an ultraviolet (UV) detector demands that
the analyte of interest must have an active chromophore. HPLC-UV
relies upon the retention time as well as the UV spectrum to iden-
tify and quantify metabolites. HPLC-UV is ideal for rapid analysis
and screening methods because it is simpler than more advanced
techniques/detectors, yet it requires components to have chro-
mophores. Some eicosanoids have speciﬁc chromophores, such as
leukotrienes, which contain a conjugated triene; however, many
eicosanoids lack active chromophores. Difﬁculties arise in quantify-
ing prostanoids with a UV detector as they lack good chromophores
and therefore UV detection cannot achieve necessary sensitivity
levels for biological samples. UV detection is an outdated tech-
nique for quantitation of eicosanoids. In our group derivatization of
eicosanoids has been coupled with ﬂuorescence detection using RP-
HPLC to determine bioactive prostaglandins, epoxyeicosatrienoic
acids, dihydroxyeicosatrienoic acids and hydroxyeicosatetraenoic
acids in rat brain tissue and achieved LOD’s and LOQ’s rang-
ing from 2–20 to 20–70 pg on the column respectively [33]. Yue
et al. derivatized eicosanoids with 2-(2,3-naphthalimino)ethyl-
triﬂuoromethanesulphonate (NE-OTf) and determined the limit of
derivatization reaction to be 0.625–8.75 pg/L. For ﬂuorescence
detection, reagents can derivatize the free carboxyl group of fatty
acid and pg detection limits can be reached. Throughout the deriva-
tization process care must be taken to ensure reproducibility as
interfering peaks from side reactions and degradation products can
easily occur. As technology continues to improve, LC separations
with mass spectrometry detection offer the highest sensitivity and
selectivity of the metabolites of arachidonic acid. A detailed discus-
sion of LC–MS and LC–MS/MS can be seen below.
2.2.3. Liquid chromatography–mass spectrometry, tandem mass
spectrometry
The development of advanced tandem MS  technology has been
one of the most important advances in biomarker research in the
past decade. Tandem MS/MS  instruments coupled with HPLC or
UPLC are capable of analyzing multiple analytes simultaneously as
well as reaching sensitivity limits corresponding to those achieved
by GC–MS/MS. A major advantage of LC–MS and LC–MS/MS is
that derivatization is not required, which saves time and cost.
Derivatization can introduce impurities that lead to decreased sen-
sitivity in MS  analysis. In HPLC-UV, when multiple analytes elute
as a single peak or overlapping peaks, quantitation is not possi-
ble. Difﬁculties also arise because of the sensitivity and selectivity
limits of UV detectors determined by the poor chromophores in
arachidonic acid metabolites. The co-eluting analytes can be dis-
tinguished using LC–MS/MS by ﬁltering speciﬁc ions. Tandem MS
instruments can operate in two  modes as discussed before, full-
scan mode where all fragmented ions are measured or SRM/MRM
mode, where selected ion pairs are monitored. The mass spectrum
acquired from a scanning experiment can be a useful tool in struc-
ture elucidation and is often used prior to analysis using SRM/MRM
mode to determine speciﬁc ions to monitor. LC–MS/MS offers the
highest sensitivity for analysis of eicosanoid levels in biological
samples when a SRM/MRM transition is monitored between an
intense precursor and product ion [83], and has become indispens-
able since being introduced by Margalit in 1996 [86]. SRM/MRM
is a principle tool used for quantitative analysis of the metabo-
lites of arachidonic acid in which two  stages of mass ﬁltering by
quadrupole 1 (Q1) and quadrupole 3 (Q3) provide absolute speci-
ﬁcity for the metabolites. Following ionization, precursor ions are
mass ﬁltered in Q1 and fragmented by collision-induced disso-
ciation (CID) to yield product ions that are mass ﬁltered in Q3
and detected. Recent advances in hybrid instruments can use a
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ime-of-ﬂight (TOF) or an ion trap in place of Q3 to improve the
ensitivity of the product ions. Although the sensitivity of detec-
ion of metabolites is increased using tandem MS,  some knowledge
f the metabolites contained in the sample is required prior to
nalysis. When coupling LC to MS,  solvent selection is important
s mobile phase additives and buffers can lead to ion suppres-
ion.
Quantiﬁcation of LC–MS and LC–MS/MS methods is often per-
ormed using internal standards. If stable isotope dilutions are
mplemented, calibration curves are created for each analyte
nd linearity is established over a speciﬁc range. Ideal internal
tandards would co-elute with the analyte of interest and be dif-
erentiated by MS  analysis. However, care must be taken when
electing internal standards. Foltz and Edom demonstrated that at
igh concentrations co-eluting internal standards have the poten-
ial to formation multimers that can lead to non-linear calibration
urves [88]. Mesaros et al. indicate that deuterium-labeled internal
tandards are generally separated in chromatographic analysis and
herefore could experience different ion suppression as the analyte
n biological samples [83]. Quantiﬁcation of the linearity of stan-
ards should be performed independent of the biological matrix
nd later compared to a spiked sample of the biological matrix to
ttain the most accurate results [43] (Table 1).
LC–MS and LC–MS/MS methods have been extensively used
n bioanalytical work since they combine the resolving power of
C with the detection speciﬁcity of MS.  In 1986, Yergey et al.
eveloped one of the ﬁrst LC–MS methods for analysis of novel
icosanoids in brain samples [46]. Using a Beckman HPLC sys-
em coupled to an Extrel 400-2 quadrupole MS  instrument with
 thermospray ionization source, 15-keto-prostaglandin E2 (15-
ETO-PGE2), hydroxyeicosatetraenoic acids (5-HETE, 12-HETE and
5-HETE) and leukotriene B4 (LTB4) were separated and quanti-
ated to achieve LOD’s ranging from 5 to 20 ng on the column [46].
n order to achieve desired separation and detection sensitivity,
nalysis needed to be performed on a single class in [46]. However,
ith advancing technologies, many of the limitations proposed by
arlier methods are being eliminated and limits of detection are
eaching the femtogram (fg) and pg range [87].
In more recent years, Masoodi and Nicolaou developed an
SI-LC-MS/MS method for analysis of 27 prostanoids and iso-
rostanes in biological ﬂuids and extracts such as the brain [31].
he method demonstrates linearity in the concentration range of
–100 pg/L and the LOD and LOQ were 0.5–50 and 2–100 pg
espectively [31]. LC–MS/MS was performed on a Waters Alliance
695 HPLC coupled to an ESI Triple Quadrupole Quattro Ultima
ass Spectrometer (Waters, Elstree, Hertsfordshire, UK) operating
n negative ion mode. LC separation was accomplished on a Gem-
ni C18 column (5 m,  2 × 150 mm)  (Phenomenex, Macclesﬁeld,
K) using a gradient system with mobile phase A – acetoni-
rile/water/glacial acetic acid (45:55:0.02, v/v/v) and mobile phase
 – acetonitrile/water/glacial acetic acid (90:10:0.02, v/v/v) [31].
he collision energy and product ions were optimized for each
ompound. The selected transitions were PGE2 (m/z 351 → 271),
GF2 (m/z 353 → 193), 6-keto-PGF1 (m/z 369 → 163), PGE3 (m/z
49 → 269), TXB2 (m/z 369 → 169), 8-iso-PGF2 (m/z 353 → 193),
-iso-15-keto PGF2 (m/z 351 → 315) and PGD3 (m/z 349 → 269)
31]. Masoodi et al. elected to use the same transition for the iso-
aric metabolites PGE1 and PGD1, PGE2 and PGD2, PGE3 and PGD3,
GJ2 and 12-PGJ2 as well as PGF2 and its isomer 8-iso-PGF2
s they were separated chromatographically. Finally, detection of
o-eluting prostanoids PGE1 and PGE2 was performed using two
RM  transitions (m/z 353 → 317 and m/z  351 → 271 respectively).
asoodi et al. describe difﬁculties in detecting 8-iso-15-keto PGF2
nd 8-iso-PGE2 as a result of metabolites having the same ion-pair
ransition. Although 8-iso-15-keto PGF2, 8-iso-PGE2 and PGD2 are
hromatographically resolved, 8-iso-PGE2 co-elutes with PGE2 andgr. B 964 (2014) 50–64
both possess the same ion-pair transition; therefore only one or the
other can be detected.
Yue et al. developed one of the ﬁrst MS  based methods for simul-
taneous identiﬁcation and quantiﬁcation of PGs, DiHETrEs, HETEs,
EETs and the parent compound AA in biological tissues, includ-
ing brain tissue [43]. This is a sensitive, speciﬁc and robust LC–MS
method for simultaneously analyzing parent compound AA and its
COX, CYP450 and LOX pathway metabolites PGs, DiHETEs, HETEs,
EETs, including PGF2, PGE2, PGD2, PGJ2, 14,15-DiHETrE, 11,12-
DiHETrE, 8,9-DiHETrE, 5,6-DiHETrE, 20-HETE, 15-HETE, 12-HETE,
9-HETE, 8-HETE, 5-HETE, 14,15-EET, 11,12-EET, 8,9-EET and 5,6-
EET in rat cortical brain tissue [43]. An Agilent 1100 LC/MSD was
used for separation and detection of the listed metabolites. Gradi-
ent separation was  performed on a Waters Symmetry® C18 column
(4.6 mm × 250 mm,  5 m)  (Waters Corporation, USA) with mobile
phase A and B consisting of 0.1% formic acid in deionized water
and acetonitrile respectively. The mobile phase gradient consisted
of 60–80% B in 30 min; 80–85% B in 5 min; 85–100% B in 1 min; 100%
B for 9 min. SIM was  performed in negative mode and the ions mon-
itored were: m/z 353 (PGF2), m/z 351 (PGD2 and PGE2), m/z 333
(PGJ2), m/z 355 (PGD2-d4) and m/z 357 (PGF2-d4) from 0 to 7 min
using a gain of 2; ions with m/z 337 (DiHETrEs), m/z 319 (HETEs and
EETs) and m/z 327 (HETE-d8 and EET-d8) from 7 to 23 min  using a
gain of 2; and ions with m/z 303 (AA) and m/z  311 (AA-d8) from
23 to 45 min  using a gain of 1 [43]. Using ESI in negative mode the
metabolites readily ionize to form carboxylate anions. The linear
range of the PGs, DiHETrEs, HETEs, EETs and AA was determined
to be 1–4500 pg and the levels of these metabolites in brain sam-
ples ranged from 1.24 to 3.90 pg/mg EETs, 2.16–12.14 pg/mg HETEs,
1.51–3.60 pg/mg PGE2 and 12,512–47,727 pg/mg AA wet  weight.
Kingsley and Marnett illustrate a LC–MS/MS method for anal-
ysis of neutral eicosanoids in various tissues, including brain in
[48]. Although this particular method analyzes PG-like products,
its applicability to related compounds is discussed. Brieﬂy, chro-
matographic separation was accomplished on a Waters 2690 HPLC
(Milford, MA)  and SRM analyses were performed on ThermoFinni-
gan TSQ 7000 or Quantum Triple Quadruple MS  with an ESI source
(ThermoFinnigan, San Jose, CA) [48]. Speciﬁc SRM transitions are
indicated for each compound with many of the PG-like compounds
yielding the highest abundance precursor ion [M + NH4]+ [48]. MS
analysis was  performed in positive mode because the PG-like com-
pounds do not deprotonate to generate a strong signal in negative
mode like prostaglandins. The authors suggest that prostaglandins
will behave similarly to the PG-like compounds because of basic
similarities in their structures [48]. The LOD’s of these compounds
ranged from 5 to 25 femtomol (fmol) on the column. This method
is applied to neutral eicosanoids and a thorough investigation on
its application for the metabolites of arachidonic acid should be
considered.
Golovko and Murphy improved a LC–MS/MS procedure for
analysis of prostanoids in the brain [39]. Four extractions were
compared to determine the optimal conditions for minimal chem-
ical background noise in MS  analysis resulting from the complex
brain biological matrix. This method requires only 10 mg of brain
tissue and enhanced the LOD for prostanoids 4–20-fold in brain
tissue from previous methods [39]. Separation of PGE2, PGD2,
PGF2, TXB2 and 6-oxo-PGF1 was performed on a Luna C18 col-
umn  (3 m,  100 A˚ pore diameter, 150 × 2.0 mm;  Phenomenex,
Torrance, CA) using an Agilent 1100 Series LC (Agilent Tech-
nologies, Santa Clara, CA) [84]. The following gradient system
was applied using 0.1% formic acid in water (mobile phase A)
and acetonitrile (mobile phase B): 10% B for 2 min, 10–65% B
from 2 to 8 min, 65–90% B from 15 to 20 min, 90–10% B from
35 to 37 min  with an equilibration between runs for 13 min.
Quantitation was  optimized and performed in MRM  mode on a
quadrupole MS  (API3000; Applied Biosystems, Foster City, CA)
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Table 1
Methods for extraction and analysis of arachidonic acid metabolites.
Reference Target analyte Sample matrix Extraction Separation/
Detection
LOD, LOQ Recovery
(%)
Linearity Chromatographic
features
Mass spectrometer
features
Analysis
time
Abdel-Halim
et al. [94]
PGE2, PGF2 Sprague–Dawley
rat brain
Centrifuge, Liq
(Ethyl acetate)
GC–MS 5 ng/g, n.r. n.r. n.r. 5 ft.column of 1%
SE-30
Molecular ion minus
trimethyl silyl ether
(M+-90), PGF2,-DO
(494)
∼3 min
Saunders  et al.
[37]
PGE1, TXB2,
6keto-PGF1 ,
PGF2 , AA
Bovine brain Liq/Liq (Hexane:
2-propanol)
RP-HPLC-UV n.r. 87.8–94.1 n.r. Zorbex-ODS
(4.6 × 250 mm),
ABS −192 nm
N/A 30 min
Ogorochi  et al.
[58]
PGE2, PGD2, PGF2 ,
6-KETO-PGF2
Human brain SPE (C18
Sep-PAK)
GC–MS n.r. n.r. n.r. Thermostable
cross-linked OV-1
fused silica
capillary column
(0.31 × 0.31 mm)
PGE2 and PGD2
(552.3540), PGF2
(625.4140),
6-KETO-PGF2
(670.4354)
11 min
Yergey  et al.
[46]
15-HETE, 12-HETE,
5-HETE, LTB4,
15-KETO-PGE2
Rat brain SPE (C18
Sep-PAK)
RP-HPLC-
(Positive
Ion)TSP-MS
5–20 (ng
on-
column),
n.r.
n.r. n.r. Du Pont
(4.6 × 250 mm),
Zorbex-ODS (5 m,
4.6 × 250 mm)
Scanning (110–510 Da) 33 min
Birkle  et al. [72] PGE2, PGD2, TXB2,
LTB4, 6keto-PGF1 ,
PGF2 , 15-HETE,
12-HETE, 5-HETE
Rat brain Liq/Liq (chloro-
form:methanol),
liq/liq
(hexane:2-
propanol)
RP-HPLC-ﬂow
scintillation
detection
n.r. 93 n.r. RadialPAK
pBondapak C18
column (10 m,
8 × 100 mm)
N/A 100 min
Yasaka  et al.
[44]
AA Mouse brain Liq (Single-Step
Methanol)
RP-HPLC-FLD 4 fmol, n.r. 95 n.r. Chemcosorb 5C8
(5 m,
4.6 × 150 mm), EX
– 259 nm and EM –
394 nm
N/A 20 min
Amruthesh
et  al. [75]
PGE2, 20-OH-LTB4,
LTB4, LXA4,
6keto-PGF1 ,
14,15-DiHETrE,
8,9-DiHETrE,
5,6-DiHETrE,
15-HETE, 12-HETE,
5-HETE, 14,15-EET,
8,9-EET, 5,6-EET,
AA
Male ICR mouse
brain
Liq (ethyl
acetate)
RP-HPLC-ﬂow
scintillation
detection,
NP-HPLC,
GC-EI-MS,
GC-EICI-MS
n.r. n.r. n.r. Radial-PAK A C18
(4 m,
8 × 100 mm),
pPorasil Radial-Pak
A (4 m,
8 × 100 mm),
Hewlett-Packard
Ultra-1
cross-linked
methyl silicone
capillary column
(25 m)
Methyl ester
trimethylsilyl ether
derivatives of 15-HETE,
12-HETE, 5-HETE were
analyzed by SIM on
predominant ions, PFB
esters of 14,15-EET,
5,6-EET were analyzed
(319, 301)
120, 40,
11.67,
16.67 min
Wiswedel et al.
[79]
12-HHT, 2-HETE,
3-HETE, 5-HETE,
8,9-HETE,
11,12-HETE,
15-HETE,
8-iso-PGF2 ,
9 ,11-PGF2 ,
9 ,11-PGF2
Rat brain
mitochondria
SPE (C18, NH2) GC-NICI-MS ∼fmol level n.r. n.r. DB 5-MS column
(30 m × 0.25 mm
i.d.; 0.25 mm ﬁlm
thickness)
12-HHT (SIM of
carboxylate anion
[M−181]− at m/z 357)
2-HETE, 3-HETE, 5-HETE,
8,9-HETE, 11,12-HETE,
15-HETE (SIM of
carboxylate anion
[M−181]− at m/z 399)
8-iso-PGF2 ,
9 ,11-PGF2 ,
9 ,11-PGF2 (SIM of
carboxylate anion
[M−181]− at m/z 569)
30,
32.2 min
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Table 1 (Continued)
Reference Target analyte Sample matrix Extraction Separation/
Detection
LOD, LOQ Recovery
(%)
Linearity Chromatographic
features
Mass spectrometer
features
Analysis
time
Rosenberger
et al. [84]
PGE2, PGD2, TXB2,
PGF1 , PGF2
Rat brain Liq/Liq
(n-Hexane/2-
Propanol)
GC-FID n.r. n.r. n.r. SP 2330 capillary
column
(30 m × 0.32 mm
i.d.)
N/A 20 min
Yue  et al. [33] PGF2 , PGE2, PGD2,
PGJ2,
14,15-DiHETrE,
11,12-DiHETrE,
8,9-DiHETrE,
20-HETE, 15-HETE,
12-HETE,
14,15-EET,
11,12-EET, 8,9-EET,
AA
Male
Sprague–Dawley
rat brain
SPE (Oasis®HLB) RP-HPLC-FLD,
RP-HPLC-
(negative
ion)ESI-MS
2–20,
20–70 (pg
on-
column)
72.7–117.2 70–2000 pg Symmetry® C18
column (5 m,
2.1 × 150 mm), EX
– 260 nm and EM –
396 nm
PGF2 (646 Da), PGE2 and
PGD2 (644 Da), PGJ2
(626 Da), 14,15-DiHETrE
(631 Da), 11,12-DiHETrE
(631 Da), 8,9-DiHETrE
(631 Da), 20-HETE
(612 Da), 15-HETE
(612 Da), 12-HETE
(612 Da), 14,15-EET
(612 Da), 11,12-EET
(612 Da), 8,9-EET
(612 Da), AA (596 Da)
100 min
Masoodi et al.
[31]
PGE1, PGD1, PGE2,
PGD2, PGF2 ,
8-iso-PGF2 ,
6-keto-PGF1 ,
PGE3, PGD3, TXB2,
TXB3,
8-iso-15-keto
PGF2 , PGJ2,
12-PGJ2, PGB2,
15-deoxy-12,14-
PGJ2, PGF3 ,
8-iso-PGE2,
8-iso-15-keto
PGE2,
13,14-dihydro
PGE1, 13,14-
dihydro-15-keto
PGE1, 13,14-
dihydro-PGF1 ,
13,14-dihydro-15-
keto PGF1 ,
13,14-dihydro-15-
keto PGE2,
13,14-dihydro
PGF2 , 13,14-
dihydro-15-keto
PGF2
Male Wistar rat
brain
SPE
(Phenomenex
C18-E)
RP-HPLC-
(Negative
Ion)ESI-MS/MS
0.5–50,
2–100 (pg
on-
column)
83–116 1–100 pg/L Phenomenex
Gemini C18 (5 m,
2.0 × 150 mm)
PGE1 and PGD1
(353 → 317), PGE2 and
PGD2 (351 → 271), PGF2
and 8-iso-PGF2
(353 → 193),
6-keto-PGF1
(369 → 163), PGE3 and
PGD3 (349 → 269), TXB2
(369 → 169), TXB3
(367 → 169),
8-iso-15-keto PGF2
(351 → 315), PGJ2 and
12-PGJ2 (353 → 193),
PGB2 (333 → 175),
15-deoxy-12,14-PGJ2
(315 → 271), PGF3
(351 → 193), 8-iso-PGE2
(351 → 315),
8-iso-15-keto PGE2
(349 → 113),
13,14-dihydro PGE1
(355 → 337),
13,14-dihydro-15-keto
PGE1 (353 → 335),
13,14-dihydro-PGF1
(357 → 113),
13,14-dihydro-15-keto
PGF1 (355 → 193),
13,14-dihydro-15-keto
PGE2 (351 → 333),
13,14-dihydro PGF2
(355 → 311),
13,14-dihydro-15-keto
PGF2 (353 → 113)
30 min
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Yue et al. [43] PGF2 , PGE2, PGD2,
PGJ2,
14,15-DiHETrE,
11,12-DiHETrE,
8,9-DiHETrE,
5,6-DiHETrE,
20-HETE, 15-HETE,
12-HETE, 9-HETE,
8-HETE, 5-HETE,
14,15-EET,
11,12-EET, 8,9-EET,
5,6-EET
Male
Sprague–Dawley
rat brain
SPE (Oasis®HLB) RP-HPLC-
(Negative
Ion)ESI-MS
n.r., 2–20
(pg on-
column)
54.84–99.56 2–2400 pg Symmetry® C18
column (3.5 m,
2.1 × 150 mm)
PGF2 (353), PGE2 and
PGD2 (351), PGJ2 (333),
14,15-DiHETrE (337),
11,12-DiHETrE (337),
8,9-DiHETrE (337),
5,6-DiHETrE (337),
20-HETE (319), 15-HETE
(319), 12-HETE (319),
9-HETE (319), 8-HETE
(319), 5-HETE (319),
14,15-EET (319),
11,12-EET (319), 8,9-EET
(319), 5,6-EET (319)
35 min
Masoodi  et al.
[54]
15-HETE, 12-HETE,
11-HETE, 9-HETE,
8-HETE, 5-HETE,
LTB4
Male Wistar rat
brain
SPE
(Phenomenex
C18-E)
RP-HPLC-
(negative
ion)ESI-MS/MS
10–20,
20–50 (pg
on-
column)
76–122 1–100 pg/L Luna C18 column
(5 m,
2.0 × 150 mm)
15-HETE (351.2 → 175),
12-HETE (351.2 → 179),
11-HETE (351.2 → 167),
9-HETE (351.2 → 155),
8-HETE (351.2 → 123),
5-HETE (319 → 115),
LTB4 (335 → 195)
28 min
Golovko  et al.
[39]
PGD2, PGE2, TXB2,
6-oxo-PGF1 ,
PGF2
Mouse brain Acetone,
followed by
Liq/Liq
puriﬁcation
RP-HPLC-
(negative
ion)ESI-MS/MS
0.6–3.3 (pg
on-
column),
n.r.
85–95 n.r. Luna C18 (3 m,
100 A˚,
2.0 × 150 mm)
PGD2 and PGE2
(351.2 → 271.5), TXB2
(369.2 → 169.2),
6-oxo-PGF1
(369.2 → 163.4), PGF2
(353.3 → 193.2)
17 min
Farias  et al. [66] AA, DHA, DPA,
E2/D2-IsoPs, PGF2 ,
8-iso-PGF2 , TXB2,
5-HETE, 5-oxo-ETE,
12-HETE, LTC4,
LTB4
Male Fischer
CDF
(F-344)/CrlBR
rat brain
SPE (Strata
C18-E), SPE
(Oasis®HLB)-
IsoPs
RP-HPLC-
(Negative
Ion)ESI-MS/MS
n.r.,
0.16–1.15 pmol
60–70 n.r. Colombus RP-C18
column (5 m,
1 × 150 mm)
AA (303 → 205); DHA
(327 → 283); DPA
(329 → 285); E2/D2-IsoPs
(351 → 271),
(351 → 233),
(351 → 333),
(351 → 315); PGF2 and
8-iso-PGF2 (353 → 193);
TXB2 (369 → 169);
5-HETE (319 → 115);
5-oxo-ETE (317 → 13);
12-HETE (319 → 179);
LTC4 (624 → 272); LTB4
(335 → 195)
45 min
Milatovic  et al.
[81]
F2-isoprostanes, AA Neuronal tissue Liq/Liq (Folch
Method) SPE
(Sep-Pak Plus
C18 cartridge)
GC-NICI-MS ∼5 pg, (low
pg range)
n.r. n.r. DB1701 fused silica
capillary (15 m,
0.25-mm diameter,
0.25-m ﬁlm
thickness)
F2-isoprostanes (569) ∼15 min
60
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Table 1 (Continued)
Reference Target analyte Sample matrix Extraction Separation/
Detection
LOD, LOQ Recovery
(%)
Linearity Chromatographic
features
Mass spectrometer
features
Analysis
time
Miller et al.
[52]
20-HETE, 15-HETE,
12-HETE,
14,15-EET,
11,12-EET, 8,9-EET,
14,15-DiHETrE,
11,12-DiHETrE,
8,9-DiHETrE,
5,6-DiHETrE
Sprague–Dawley
rat brain cortical
tissue
SPE (Oasis®HLB) RP-UPLC-
(negative
ion)ESI-MS/MS
n.r.,
0.208 ng/L
72.73–94.11 0.208–33.3 ng/LACQUITY BEH C18
column (1.7 m,
2.1 × 100 mm)
20-HETE
(319 → 245,289),
15-HETE (319 → 219),
12-HETE (319 → 179),
14,15-EET (319 → 219),
11,12-EET (319 → 167),
8,9-EET (319 → 127),
14,15-DiHETrE
(337 → 207),
11,12-DiHETrE
(337 → 167), 8,9-DiHETrE
(337 → 127), 5,6-DiHETrE
(337 → 145)
4.8 min
Brose  et al. [49] PGD2, PGE2,
8-isoPGE2,
ent-PGE2,
11-PGE2,
5trans-PGE2,
15R-PGD2
Mouse brain
(Ischemic Brain
Tissue)
Acetone using
Liq/Liq
RP-HPLC-
(Negative
Ion)ESI-MS/MS,
Chiral-HPLC-
(Negative
Ion)ESI-MS/MS
0.3 ± 0.1
(pg on-
column)
∼90 1 pg–100 ng
on-column
Luna C-18 (3 m,
100 A˚,
2.0 × 150 mm), 2
Tandem Chiral Lux
Amylose 2 columns
(3 m, 100 A˚,
2.0 × 150 mm)
PGD2 (351.2 → 189.5),
PGE2 (351.2 → 189.5),
8-isoPGE2
(351.2 → 189.5),
ent-PGE2
(351.2 → 189.5),
11-PGE2
(351.2 → 189.5), 5
trans-PGE2
(351.2 → 189.5),
15R-PGD2
(351.2 → 189.5)
65 min
Dumlao  et al.
[45]
141 eicosanoid
metabolites
generated from
cycloxygenase,
lipoxygenase,
cytochrome P450
enzymes and
non-enzymatic
pathways
Application in
various tissue,
cerebral spinal
ﬂuid presented
SPE (Strata-X
polymerized,
Phenomenex)
RP-HPLC-
(Negative
Ion)ESI-MS/MS
0.1–1,
1–10 pg
n.r. n.r. Synergi RP-C18
column
(2.1 × 250 mm)
See reference for speciﬁc
transitions and
optimized parameters for
141 eicosanoid
metabolites
25 min
Yang  et al. [77] AA Male Wistar
Rats (traumatic
brain injury)
Liq (methanol) GC-EI-MS n.r. n.r. n.r. 30-m DB-5 column
(30 m × 250 m
i.d., 0.25 m ﬁlm
thickness)
Full Scan (30–550) 59 min
Strauss  et al.
[62]
15-HETE, 12-HETE,
11-HETE, 8-HETE,
5-HETE, 14,15-EET,
11,12-EET, 8,9-EET,
5,6-EET
Mouse brain SPE (Oasis®HLB) RP-UPLC-
(Negative
Ion)-MS/MS
n.r., n.r. 25–50 1–125 pg ACQUITY BEH C18
column (1.7 m,
2.1 × 100 mm)
Employed multiple
reaction mode (MRM),
exact MRM  transitions
not listed
8 min
Brose  et al. [42] PGD2, PGE2,
8-isoPGE2,
15R-PGE2,
ent-PGE2,
12-PGD2,
11-PGE2,
5trans-PGE2,
15R-PGD2
Mouse Brain
(Ischemic Brain
Tissue)
Liq (Single-step
Methanol)
RP-UPLC-
(Negative
Ion)ESI-MS/MS
n.r., 1 ± 0.5
(pg on-
column)
92.9 ± 12.1
–96.7 ± 9.9
1 pg–50 ng ACQUITY UPLC HSS
T3 column (1.8 m,
100 A˚,
2.1 × 150 mm)
PGE2
(351.2171 → 189.1279),
PGE2-d4
(355.2391 → 275.2391)
4.5 min
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using a turbo-ion-spray ionization source and the following MRM
transitions were monitored: PGE2 and PGD2 (m/z 351.2 → 271.5),
PGF2 (m/z 353.3 → 309.3), TXB2 (m/z 369.2 → 169.2) and 6-oxo-
PGF1 (m/z 369.2 → 163.4) [84]. The LOD’s reported in picograms
on the column were PGE2/PGD2 (0.5 ± 0.1), TXB2 (0.7 ± 0.2), PGF2
(1.2 ± 0.1) and 6-oxo-PGF1 (2.1 ± 0.5). Additionally, the mass
in nanograms/gram wet weight for 20 mg brain samples was
determined to be PGE2/PGD2 (0.1 ± 0.0), TXB2 (0.1 ± 0.0), PGF2
(0.1 ± 0.0) and 6-oxo-PGF1 (0.3 ± 0.1) [84]. This method effectively
separated all the prostaglandins and isoprostanes of interest except
PGE2 and 8-iso-PGE2, which co-eluted. Results were consistent
with those reported by Masoodi et al. and who performed analysis
of isoprostanes and prostaglandins using similar chromatographic
parameters [31,85].
Biomarker discovery for application in pharmacological
approaches is becoming increasingly important. Masoodi et al.
present a LC–MS/MS system for analysis of seven arachidonic acid
metabolites in brain samples of Wistar rats [54]. This approach
can be used in combination with [31] for various lipidomic
applications. One of the challenges of analysis of arachidonic
acid metabolites is achieving suitable sensitivity in detection.
Single quadrupole MS  instruments offer increased sensitivity over
diode array detection, but are limited by certain factors such as
chromatographic separation. MRM  mode allows for increased
sensitivity of detection by increasing the speciﬁcity for each
metabolite. Analysis of 5-HETE, 8-HETE, 9-HETE, 11-HETE, 12-
HETE, 15-HETE, LTB4 and 12S-HETE-d8 was performed using a Luna
C18 column (5 m,  2 mm × 150 mm;  Phenomenex, Macclesﬁeld,
UK) on a Waters Alliance 2695 HPLC system coupled to a Triple
Quadrupole Quattro Ultima Mass Spectrometer (Waters, Elstree,
Hertsfordshire, UK). Chromatographic separation was achieved
using isocratic conditions at 95:5 (A:B) consisting of mobile phase
A (methanol/water/glacial acetic acid, 80:20:0/02, v/v/v) and
mobile phase B (acetonitrile/water/glacial acetic acid, 45:55:0.02,
v/v/v). MRM  transitions were optimized for the highest abundance
product ions and the ones documented by this method were:
5-HETE (m/z 319 → 115), 8-HETE (m/z 319 → 155), 9-HETE (m/z
319 → 123), 11-HETE (m/z 319 → 167), 12-HETE (m/z 319 → 179),
15-HETE (m/z 319 → 175) and LTB4 (m/z 335 → 195) [54]. Isobaric
8-HETE and 12-HETE were not able to be resolved chromatograph-
ically; however, because they possess structure speciﬁc fragment
ions simultaneous detection is possible in this method. LOD’s and
LOQ’s are reported ranging from 10 to 20 pg on the column and
20–50 pg on the column respectively. The method of Masoodi et al.
demonstrate adequate sensitivity for detection of arachidonic acid
metabolites in brain samples.
Although HPLC–MS/MS has been at the forefront of quantitating
biomarkers in biological samples, currently UPLC–MS/MS is becom-
ing the frontrunner as it overcomes limitations of traditional HPLC
such as low ﬂow rate and large injection volumes. Miller et al. devel-
oped a high throughput UPLC–MS/MS method for quantitation
of hydroxyeicosatetraenoic acid (HETE), dihydroxyeicosatrienoic
acid (DiHETrE), and epoxyeicosatrienoic acid (EET) metabolites of
arachidonic acid in rat brain cortical tissues with a potential appli-
cation in assessing the risk of symptomatic cerebral vasospasm
(SV) in subarachnoid hemorrhage (SAH) patients [52]. UPLC meth-
ods are designed to utilize efﬁcient separation to reduce run
times. Chromatographic separation was performed on an ACQUITY
UPLC (Waters, Milford, MA)  using a BEH C18 column (1.7 m,
2.1 mm × 100 mm)  (Waters, Milford, MA)  with mobile phases con-
sisting of A – 0.005% acetic acid, 5% acetonitrile in deionized
water and B – 0.005% acetic acid in acetonitrile [52]. The follow-
ing parameters were used for the mobile phase gradient: 0–4 min
(35–70% B), 4–4.5 min  (70–95% B) and 4.5–4.8 min (95% B). Quan-
titation was  executed in negative SRM mode using a TSQ Quantum
Ultra (Thermo Fisher Scientiﬁc, San Jose, CA) triple quadrupole
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ass spectrometer coupled with heated electrospray ionization
HESI) [52]. The MS  parameters were optimized to achieve the
ighest [M−H]− ion abundance and the following m/z  transitions
ere used: 20-HETE (319 → 245), 15-HETE (319 → 219), 12-
ETE (319 → 179), 14,15-EET (319 → 219), 11,12-EET (319 → 167),
,9-EET (319 → 127), 14,15-DiHETrE (337 → 207), 11,12-DiHETrE
337 → 167), 8,9-DiHETrE (337 → 127), 5,6-DiHETrE (337 → 145)
nd 20-HETE-d6 (319 → 251) respectively. The LOQ for all the
etabolites studied was 0.208 ng/mL and samples from rat brain
ortex tissue demonstrated levels of 20-HETE, 15-HETE, 12-HETE,
,9-EET 14,15-DiHETrE and 11,12-DiHETrE ranging from 0.57 to
3.99 pmol/g wet tissue. The matrix effect was monitored by
etermining the coefﬁcient of variance (CV) for the peak areas of
ach metabolite at low and high concentration levels. Both levels
emonstrated CV’s lower than 15%, exemplifying the consistency
f the assay. Miller et al. report a reliable method for analysis of 10
rachidonic acid metabolites in several tissues, including the brain
nd demonstrates advantages over other methods [68,69] used for
nalysis of similar metabolites, such as shortened run times from
7 and 31 min  to 6.4 min.
With advancing MS  technology the development of high-
hroughput methods is escalating. Tandem MS  methods are limited
y the number of transitions that can be monitored [83]. Over-
oming this issue, a targeted comprehensive lipidomic analysis by
eparation simpliﬁcation (CLASS) approach is presented by Dum-
ao et al. in which an eicosanoid methodology demonstrates the
bility to monitor and quantitate 171 scheduled multiple reac-
ion monitoring (sMRM) pairs [45]. A MRM  pair correlated to a
peciﬁc LC retention time is referred to as an sMRM pair [45].
he principal constraint of this method is the amount of stan-
ard metabolites available. As more standards become accessible
he efﬁciency and application of this method will be increased.
he present method can be applied to various tissues, but is
tilized here for analysis of cerebral spinal ﬂuid (CSF). Chro-
atographic separation was performed on a Synergi RP-C18
olumn (2.1 × 250 mm,  Phenomenex, CA) using mobile phases A
nd B, comprised of water/acetonitrile/acetic acid (70:30:0.02,
/v/v) and acetonitrile/isopropyl alcohol (50:50, v/v) respectively
45]. The mobile phase gradient applied was 1–3 min  (0–25% B),
–11 min  (25–45% B), 11–13 min  (45–60% B), 13–18 min  (60–75%
), 18–18.5 min  (75–90% B), 18.5–20 min  (90% B), 20–21 min
90–0% B) and 21–25 min  (0% B) [45]. Tandem MS  analysis in sMRM
ode using an ABI/Sciex (Foster City, CA) 4000 QTRAP hybrid, triple
uadrupole linear ion trap mass spectrometer with a Turbo V ion
ource achieved LOD’s ranging from 0.1 to 1 pg [45]. Dumlao et al.
stablished for each eicosanoid the precursor ion, product ion, LOD,
eclustering potential and collisional energy applied [45]. It was
vident that analyzing 171 metabolites does not allow for com-
lete chromatographic separation and detection by MS  became
ifﬁcult, as many metabolites had only slight modiﬁcations in their
olecular structure and produced the same product ions. However,
pplication of sMRM mode allows for detection of similar metabo-
ites by using associated retention times. The sMRM approach
emonstrated its detection effectiveness when analyzing a cluster
f metabolites with overlapping chromatographic peaks in Dumlao
t al. [45]. This method takes advantage of advanced mass spec-
rometer algorithms, optimizes data collection and is anticipated
s a starting point for future eicosanoid research of large data sets
45].
The work of Brose et al. demonstrates a single step extrac-
ion UPLC–MS/MS method for analysis of the E2/D2 series
rostaglandins and isoprostanes in brain tissue [42]. This
PLC–MS/MS method improves an HPLC–MS/MS method pre-
iously reported [49]. Lengthy separation times result in broad
hromatographic peaks that decrease detection limits and in turn
imit sensitivity in MS  analysis. The UPLC–MS/MS improves thegr. B 964 (2014) 50–64
separation time of major isobaric iso-PGE2 of the HPLC method
from 1 h to 4 min. Utilizing a single solvent (methanol) for extrac-
tion purposes, proved to decrease chemical background noise and
increase MS  sensitivity. Separation of PGE2 and PGD2 was exe-
cuted on an ACQUITY HSS T3 column (1.8 M,  100 A˚ pore diameter,
2.1 × 150 mm,  Waters, Milford, MA)  with a Waters Acquity UPLC
(Waters, Milford, MA). A simple aqueous solvent system consist-
ing of 0.1% formic acid in water (mobile phase A) and acetonitrile
(mobile phase B) was used to perform the following gradient:
39% B for 0.5 min, 39–40.5% B over the next 6.88 min, 40.5–98%
B over the next 0.2 min  and 98% B for 2 min  [42]. Separation of the
PGE2 and PGD2 occurred within 4 min  making this an extremely
fast method. An issue Brose exposed when using methanol as a
sole means of extraction was  that hydrophobic lipids would not
elute from the column and therefore extensive cleaning is required
if brain samples are frequently analyzed [42]. Quantiﬁcation of
PGE2 and PGD2 was  performed using a Quadrupole Time-of-Flight
Mass Spectrometer (Q-TOF, Synapt G2-S, Waters, Milford, MA)
monitoring the MRM  transition (m/z 351 → 189). Linearity was
established for the concentration range of 1 pg–50 ng on the col-
umn  for the analytes, and the LOQ was determined to be 1 ± 0.5 pg
[42]. This method was  applied to quantify endogenous levels of
E2/D2 prostaglandins and isoprostanes in ischemic brain tissue
and determined PGD2 and PGE2 to be present at 1.02 ± 0.06 and
5.07 ± 0.33 ng/gww respectively. Additionally it increases sensitiv-
ity of analysis while decreasing time and cost of analysis, and is
proven effective for detection of prostaglandins. Although Brose
et al. present a desirable UPLC–MS/MS method for analysis of
prostaglandins and isoprostanes in brain tissue, it falls short on
achieving the separation of PGE2 and 15R-PGE2 as well as PGE2
and ent-PGE2. Chromatographic resolution of PGE2 and ent-PGE2
is important, as it has been suggested that analysis of their ratio may
lead to demonstrating the origin of PGE2 in biological samples [49].
Chiral separation of PGE2 and ent-PGE2 was performed on two  Lux
Amylose2 columns (3 m,  100 A˚ pore diameter, 150 × 2.0 mm;  Phe-
nomenex) connected in series using an acetonitrile/water/formic
acid gradient and quantiﬁcation was accomplished in MRM  mode,
monitoring the precursor and product ions m/z 351.2 and 189.5
respectively. Brose et al. optimized MS/MS  parameters to achieve
the highest selectivity for 15-series isoPGE2 [49]. Product ions pro-
duced from PGE2 are generated by a water and carboxyl group
loss. As a result, product ions 333, 315 and 271 are not speciﬁc
toward 15-series isoPGE2. The 189.5 product ion is generated by a
side chain loss (–C6H10, –CO2, –H2O × 2), which allows for selective
quantitation for 15-series isoPG and eliminates up to 48 possi-
ble isoforms [49]. Brose et al. determined that the 189.5 product
ion demonstrates high speciﬁcity and selectivity than previously
published methods using 351 → 271 transition [49]. The detection
limits reported were 0.3 ± 0.1 pg and the method was  applied to
analyze mouse brain ﬁxed with head-focused microwave irradia-
tion before and after global ischemia [49]. Advances in chiral UPLC
will signiﬁcantly reduce the analysis time of the reported method.
Lipidomic analysis of brain tissue from APP/tau mice and con-
trol mice at pre-symptomatic and post-symptomatic phases was
performed using RPLC-ESI-Triple Quadrupole MS/MS in [50]. Sep-
aration and quantitation of 31 arachidonic acid metabolites was
performed on an ACQUITY UPLC (Waters) system using a ACQUITY
BEH C18 column (1.7 mm × 150 mm,  1.7 m,  Waters) coupled to
a 5500 Quadrupole-Linear Ion Trap Hybrid MS  (QTRAP) (AB Sciex,
Framingham, MA,  USA) [50]. Mobile phases A and B were composed
of water/acetate (100:01, v/v) and acetonitrile/methanol (4:1, v/v)
respectively. The following gradient was  applied for measurement
of the metabolites: 0–5 min  (27–50% B), 5–35 min  (50–80% B),
35–40 min  (80–100% B) and 40–50 min  (100% B). Tajima et al.
adjusted the ﬂow rate from 50 L/min (0–35 min), 50–100 L/min
(35–40 min) and ﬁnally 100 L/min (40–50 min) to improve the
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esolution of the later eluting compounds. This particular UPLC
ethod is employed to analyze a total of 62 metabolites (31
etabolites of arachidonic acid) in 50 min. Reducing the ﬂow to
0 L/min in an UPLC instrument can drastically change the efﬁ-
iency of separation as the number of theoretical plates is affected
irectly by the mobile phase velocity. At extremely low velocity
he number of theoretical plates is the highest, which is likely
 reason the ﬂow rate of 50 L/min was chosen; however, the
onger a compound spends on the column the broader its chromato-
raphic peaks will get. Furthermore, as discussed before, broad
hromatographic peaks will decrease the sensitivity of the detec-
or. Utilization of the advances UPLC offers is not readily seen in
50]. Tajima et al. monitored fold changes (ratio of APP/tau to wild-
ype) in PGD2, TXB2, 12-HHT, 12-HETE, 15-HETE, 11,12-EpETrE and
4,15-EpETrE and observed a signiﬁcant decrease in PGD2 and 15-
ETE over 10 months, no speciﬁc concentrations and LOD’s are
eported [50].
.2.4. Ultra high pressure liquid chromatography
Separation of multiple metabolites is detailed and often
equires long chromatographic analysis time as a result of the
imitation of ﬂow rate applied in HPLC. Extensive time spent on
he column can lead to decreased sensitivity in detection due to
road chromatographic peak shapes. UPLC increases resolution,
peed and sensitivity for analysis of metabolites. The particle size
f HPLC columns has gradually decreased from 10 to 3 m the
970–1990’s, thus increasing separation efﬁciency. In a survey
omparing column usage from 1997 to 2007 a shift in interest is
een from HPLC columns of 5 m particle size to UPLC columns
f <2 m particle size [71]. A reduction in particle size to 1.7 m
UPLC columns) has demonstrated a further enhancement in the
fﬁciency of separation as described by Van Deemter’s equations.
t low linear velocities columns will experience reduced perfor-
ance; however, if the particle size is decreased an improvement
an be seen in column performance. Additionally, decreased par-
icle sizes can demonstrate less reduction in column performance
t increased linear velocities as compared to larger particle sizes.
and broadening is a consequence of long analysis times often used
n eicosanoid analysis. Broader peaks decrease the signal-to-noise
atio consequently decreasing the sensitivity of the detector.
ecreasing the height equivalent theoretical plates (HETP) by
ecreasing particle size will decrease band broadening. As a result
f increased speed of analysis, UPLC lowers use of solvent, thus
ecreasing cost and making the technique more environmentally
riendly, or “green”. Additionally, increased speed offers a higher
hroughput of analysis. With advancements in technology, UPLC
tilizes the ability to sustain pressures of 15,000 psi (1000 bar)
ompared to 5802 psi (400 bar) for traditional HPLC. Additionally
PLC columns are packed with fully porous particles or particles
hat contain a solid core. The solid core improves peak shape
s solvents and analytes are no longer able to penetrate into
article pores, hence reducing axial diffusion [67]. Kortz et al.
mproved the resolution of PGD2 and PGE2 from 1.4 to 2.9 and
educed the analysis time in half using a Kinetex core–shell
olumn rather than a standard C18 column with fully porous
articles [92]. However, difﬁculties arise when analyzing various
atrices with solid core particles, and fully porous particles may
e favored for increased permeability [67]. Brose et al. developed
 UPLC–MS/MS method to analyze the E2/D2 prostaglandins
nd isoprostanes from mouse brains in which separation was
chieved within 4 min  for the major species and with ﬁve times
arrower chromatographic peaks compared to traditional HPLC
ethods [42]. A single step extraction was employed and the
OQ for this UPLC–MS/MS method was 1 ± 0.5 pg on the column.
nhancing peak shape allows for smaller injection volumes, and
maller injection volumes can result in better resolution in the massgr. B 964 (2014) 50–64 63
spectrometer. However, in less concentrated solutions larger injec-
tion volumes are often needed and Brose et al. reported a change
in peak shape when larger volumes of analyte were injected [42].
Similarly Miller et al. reported results for analysis of 8,9-DiHETrE,
20- HETE, 15-HETE, 12-HETE in cerebral spinal ﬂuid and 12-, 15-,
and 20-HETE, 11,12- and 14,15-DiHETrE and 8,9-EET in rat brain
cortical tissue using UPLC–MS/MS that were comparable to Yue
et al., Yoshida et al. and Nueman et al. with a shortened run time
of 6.2 min  verses run times averaging >30 min  [43,52,68,69]. The
concentrations of these metabolites were linear within the range
of 0.208–33.3 ng/ml with a LOQ for all metabolites of 0.208 ng/ml
[52]. Cerebral cortex levels of EETs (5,6-EET, 8,9-EET, 11,12-EET and
14,15-EET) and HETEs (5-HETE, 8-HETE, 11-HETE, 12-HETE and
15-HETE) were reported ranging from 1 to 49 pg/mg protein in [62].
Yue et al. demonstrate detection of DiHETrE metabolites in [43].
This method [52] alludes to the difﬁculty of detecting DiHETrEs
as a result of their response being below the LOQ and suggests
further research should be investigated. Lastly, the concentration
of cyclopentenone prostaglandins (CyPGs) after temporary focal
ischemia was  determined by UPLC–MS/MS in SRM mode to range
from 1 nM to 5 M depending on the metabolite in [70]. It can be
anticipated that UPLC will become used more frequently for analy-
sis of arachidonic acid metabolites. See Table 1 for a list of methods
for extraction and analysis of arachidonic acid metabolites.
3. Conclusion
Eicosanoids are potent lipid mediators of inﬂammation and are
known to play an important role in numerous pathophysiological
processes. For that reason they are actively researched for their
roles in various diseases and applications. The desire for depend-
able analytical techniques that quantify picogram amounts or lower
of these metabolites in various biological samples is escalating. In
regards to analysis of the brain tissue, extraction of arachidonic
acid metabolites is a particularly challenging issue as a result of the
complex matrix. Solvent and SPE extractions have been discussed
that have proven to increase selectivity and sensitivity. Structure
determination and quantitation of arachidonic acid metabolites in
brain tissue can be regularly performed by GC–MS and GC–MS/MS,
but is complicated by sample preparation, analysis time and cost;
therefore, focus has shifted toward liquid chromatography. Appli-
cations of LC instruments equipped with UV detectors are limited
for eicosanoids as a result of the requirement of chromophores.
Quantitation becomes difﬁcult at levels required for analysis of
brain samples. Fluorescence detection is complicated by sample
preparation, but can offer improved results in comparison to UV
detectors. The development of LC–MS and LC–MS/MS methods has
transformed the approach to analyze arachidonic acid metabo-
lites. LC–MS and LC–MS/MS do not require derivatization, thus
reducing time and cost. In comparison to GC methods, LC–MS and
LC–MS/MS methods are more versatile and often easier to exe-
cute. Tandem MS/MS  instruments offer the highest sensitivity for
analysis of arachidonic acid metabolites in brain samples. Tandem
MS/MS  instruments operating in SRM/MRM allow for analysis of
similar eluting compounds as a result of being capable of selecting
speciﬁc ion pairs. Finally, UPLC offers increased resolution, speed
and sensitivity for analysis of metabolites. Although these instru-
ments are costly, the potential for high throughput methods has
been demonstrated. Future advances in instrumentation will allow
for higher throughput methods that are simpler to operate and offer
improved selectivity, sensitivity and lower detection limits.Acknowledgments
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